Treats schizophrenia. ANDA 208049, held by Accord Hlthcare. Lurasidone Hydrochloride.
As of Nov 16, 2026, ANDA 208049 (Lurasidone Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Jan 3, 2019, with 1 approved supplement and 0 published complete response letters.
Lurasidone hydrochloride tablets are indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia. Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression). Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression). Lurasidone hydrochloride is an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults and adolescents (13 to 17 years) ( 1, 14.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 3, 2019 | Original application | Approved | None posted |
| Lurasidone Hydrochloride20MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride40MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride60MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride80MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Lurasidone Hydrochloride120MG · tablet;oral | Lurasidone Hydrochloride | Rx |
| Jan 13, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jan 3, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters